| Literature DB >> 32156607 |
Rui Liu1, Huan Han1, Fang Liu2, Zhihua Lv1, Kailang Wu3, Yingle Liu3, Yong Feng4, Chengliang Zhu5.
Abstract
BACKGROUND: There's an outbreak of a novel coronavirus (SARS-CoV-2) infection since December 2019, first in China, and currently with more than 80 thousand confirmed infection globally in 29 countries till March 2, 2020. Identification, isolation and caring for patients early are essential to limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events. The RT-PCR detection of viral nucleic acid test (NAT) was one of the most quickly established laboratory diagnosis method in a novel viral pandemic, just as in this COVID-19 outbreak.Entities:
Keywords: COVID-19; Nucleic acid test; Positive rate; SARS-CoV-2
Mesh:
Substances:
Year: 2020 PMID: 32156607 PMCID: PMC7094385 DOI: 10.1016/j.cca.2020.03.009
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786
SARS-CoV-2 NAT positive rate of 4880 cases with their respiratory specimens by RT-PCR.
| Nuclear Acid | Sputum | Bronchoalveolar Lavage Fluid | Nasal and Pharyngeal Swabs | Total | Total Positive Rate | |||
|---|---|---|---|---|---|---|---|---|
| n | Positive Rate | n | Positive Rate | n | Positive Rate | |||
| NP | 28 | 49.12% | 4 | 80.00% | 1910 | 39.64% | 1942 | 39.80% |
| ORF1ab | 29 | 50.88% | 5 | 100.00% | 1966 | 40.81% | 2000 | 40.98% |
| Double positive | 28 | 49.12% | 4 | 80.00% | 1843 | 38.25% | 1875 | 38.42% |
SARS-CoV-2 NAT positive rate in Male and Female groups.
| Nuclear Acid | Male | Female | p value | |||
|---|---|---|---|---|---|---|
| n | Positive Rate | n | Positive Rate | |||
| NP | 943 | 41.89% | 999 | 38.00% | 7.672 | 0.006 |
| ORF1ab | 967 | 42.96% | 1033 | 39.29% | 6.739 | 0.009 |
| Double positive | 910 | 40.43% | 965 | 36.71% | 7.095 | 0.008 |
SARS-CoV-2 NAT positive rate in groups according to age.
| Nuclear Acid | 18–29 | 30–39 | 40–49 | 50–59 | 60–69 | ≥70 | p value | |
|---|---|---|---|---|---|---|---|---|
| (n = 482) | (n = 1097) | (n = 841) | (n = 1011) | (n = 886) | (n = 563) | |||
| Gender rate | 229/253 | 494/603 | 389/452 | 451/560 | 417/469 | 271/292 | 3.071 | 0.689 |
| (M/F) | ||||||||
| nCov-NP | 129 | 280 | 287 | 446 | 439 | 361 | 320.802 | <0.001 |
| nCovORF1ab | 124 | 286 | 296 | 461 | 466 | 367 | 353.547 | <0.001 |
| Double Positive | 120 | 271 | 278 | 434 | 424 | 348 | 306.946 | <0.001 |
| Double Positive Rate | 24.90% | 24.70% | 33.06% | 42.93% | 47.86% | 61.81% |
Risks of SARS-CoV-2 positive rate upon Gender and Age.
| Risk factors | Regression coefficient | p value | odds ratio | 95% CI for coefficient |
|---|---|---|---|---|
| Gender | 0.147 | 0.016 | 1.158 | 1.028–1.305 |
| Age | 0.032 | <0.001 | 1.033 | 1.029–1.037 |
These are regression coefficients adjusted for gender and age. CI = confidence interval.
SARS-CoV-2 NAT positive rate of 1707 cases from Fever Clinics.
| Nuclear Acid | Sputum | Bronchoalveolar Lavage Fluid | Nasal and Pharyngeal Swabs | Total | Total Positive Rate | |||
|---|---|---|---|---|---|---|---|---|
| n | Positive Rate | n | Positive Rate | n | Positive Rate | |||
| NP | 11 | 78.57% | 2 | 66.67% | 980 | 57.99% | 993 | 58.17% |
| ORF1ab | 12 | 85.71% | 3 | 100.00% | 1031 | 61.01% | 1046 | 61.28% |
| Double positive | 11 | 78.57% | 2 | 66.67% | 960 | 56.80% | 973 | 57.00% |
SARS-CoV-2 NAT positive rate in Fever Clinics grouped according to age.
| Nuclear Acid | 18–29 | 30–39 | 40–49 | 50–59 | 60–69 | ≥70 | p value | |
|---|---|---|---|---|---|---|---|---|
| (n = 103) | (n = 241) | (n = 292) | (n = 385) | (n = 450) | (n = 236) | |||
| Gender rate | 58/45 | 126/115 | 152/140 | 185/200 | 224/226 | 120/116 | 2.988 | 0.702 |
| (M/F) | ||||||||
| nCov-NP | 41 | 119 | 161 | 222 | 264 | 186 | 64.456 | <0.001 |
| nCovORF1ab | 41 | 127 | 168 | 234 | 289 | 187 | 62.98 | <0.001 |
| Double Positive | 40 | 118 | 157 | 219 | 258 | 181 | 58.835 | <0.001 |
| Double Positive Rate | 38.83% | 48.96% | 53.77% | 56.88% | 57.33% | 76.69% |
SARS-CoV-2 NAT positive rate in Fever Clinics in different date periods.
| Nuclear Acid | 22–29th Jan | 30th Jan–6th Feb | 7th–14th Feb | p value | ||||
|---|---|---|---|---|---|---|---|---|
| n | Positive Rate | n | Positive Rate | n | Positive Rate | |||
| NP | 152 | 53.15% | 648 | 65.59% | 193 | 44.57% | 58.205 | <0.001 |
| ORF1ab | 169 | 59.09% | 668 | 67.61% | 209 | 48.27% | 48.166 | <0.001 |
| Double positive | 152 | 53.15% | 631 | 63.87% | 190 | 43.88% | 51.148 | <0.001 |